Skip to content

Efficacy and safety of using combination of non-insulated microneedle radiofrequency alone compared to combination with polynucleotides for the treatment of periorbital wrinkle. A pilot study

Efficacy and safety of using combination of non-insulated microneedle radiofrequency alone compared to combination with polynucleotides for the treatment of periorbital wrinkle. A pilot study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20201105007
Enrollment
30
Registered
2020-11-05
Start date
2020-11-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periorbital wrinkle non&#45

Interventions

insulated microneedle radiofrequency with polynucleotides
Patients receive 3 intervention biweekly combination of non&#45
insulated microneedle radiofrequency alone compared to combination with polynucleotides for the treatment of periorbital wrinkle&#44
face study
Experimental Drug
Non&#45

Sponsors

DS Medical Systems (Thailand) Co.,Ltd.
Lead Sponsor
DermAesthetic Co.&#44
Collaborator
Ltd.
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Fitzpatrick skin type 3-5 Class 1-2 of Fitzpatrick’s Classification of Facial Wrinkling (Periorbital)

Exclusion criteria

Exclusion criteria: Allergy to hyaluronic acid or polynucleotide Pregnancy, Breast feeding, or postpartum within 3 months Has skin infection at periorbital area Using steroid, anticoagulant, anti platelet and ginkgo Smoking History of hypertrophic scar or keloid

Design outcomes

Primary

MeasureTime frame
Efficacy of using combination of non-insulated microneedle RF with polynucleotides baseline, 2 wk, 4 wk, 6 wk, 8 wk, 12 wk, 16 wk, 28 wk Photograph, Antera, Visioscan, Cutometer, Mexameter

Secondary

MeasureTime frame
Safety of using combination of non-insulated microneedle RF with polynucleotides baseline, 2 wk, 4 wk, 6 wk, 8 wk, 12 wk, 16 wk, 28 wk VAS, Side effect

Countries

Thailand

Contacts

Public ContactYanisorn Nanchaipruek

Faculty of Medicine Siriraj Hospital, Mahidol University

yanisorn.nan@mahidol.ac.th0946949454

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026